For many people living with binge eating disorder and type 2 diabetes, managing blood sugar isn’t just about counting carbohydrates or losing weight. Emotional eating, loss of control around food, and feelings of guilt can quietly interfere with diabetes care, even when someone is taking the right medications. Because of …
Read More »Why Blood Sugar Changes Every Month: Using CGM to Manage Luteal Phase Insulin Resistance
Many women with diabetes notice that blood sugar levels become harder to control during certain weeks of the month. Despite eating the same meals, taking the same insulin doses, and maintaining consistent activity levels, glucose readings may suddenly climb. This recurring pattern is often linked to luteal phase insulin resistance, …
Read More »After CGM, Is Continuous Lactate Monitoring the Next Big Breakthrough?
Continuous glucose monitoring (CGM) has fundamentally changed diabetes management by giving patients and clinicians access to real-time glucose data. As a result, treatment decisions have become more precise, and many people with diabetes now spend more time within their target glucose range. However, glucose represents only one part of the …
Read More »Does It Matter When Your Patients Eat? The New Science of Chrono-Nutrition
For decades, diabetes management has focused on what patients eat and how much they consume. However, emerging research suggests another factor deserves attention: when they eat. The growing field of chrono-nutrition research in diabetes explores how meal timing interacts with the body’s internal clock to influence glucose metabolism, insulin sensitivity, …
Read More »Beyond A1C: Could Metabolic Flexibility Become the Next Major Diabetes Biomarker?
For decades, A1C has served as the gold standard for assessing long-term glucose control in people with diabetes. However, it tells only part of the story. Researchers are now exploring whether metabolic flexibility could become an important biomarker in diabetes, offering a deeper understanding of metabolic health than A1C alone. …
Read More »Rethinking Sugar-Free: Are Artificial Sweeteners Raising Cardiovascular Risk?
For years, artificial sweeteners have been promoted as an important strategy for reducing sugar intake in people with diabetes. They help lower carbohydrate intake, reduce post-meal glucose spikes, and support weight management without adding calories. However, recent research has challenged the long-held assumption that all non-nutritive sweeteners are metabolically neutral. …
Read More »Your Patient Is Taking a Compounded GLP-1. Now What?
As demand for GLP-1 receptor agonists continues to outpace supply, many patients have turned to compounded medications obtained through telehealth companies, medical spas, wellness clinics, and compounding pharmacies. While these products may improve access for some individuals, they also introduce important clinical, regulatory, and medicolegal challenges. Providers increasingly encounter patients …
Read More »Maxed Out on Medications, Not Ready for Surgery: Is Metabolic Endoscopy the Missing Middle Ground?
For many people living with type 2 diabetes, treatment eventually reaches a frustrating crossroads. Despite multiple medications, including GLP-1 receptor agonists, SGLT2 inhibitors, and insulin, glycemic targets may remain difficult to achieve. Meanwhile, bariatric surgery can produce major metabolic benefits, but its invasiveness limits acceptance for many patients. This treatment …
Read More »The Diabetes Complication Nobody Sees Coming: Cognitive Decline in Midlife Adults
For decades, diabetes care has focused on preventing complications such as retinopathy, nephropathy, neuropathy, and cardiovascular disease. Yet another complication may be developing much earlier and often without obvious symptoms: diabetes-related cognitive decline. While memory loss and dementia have traditionally been viewed as concerns of older age, growing evidence suggests …
Read More »The First Disease-Modifying Treatment After a Type 1 Diabetes Diagnosis: Why Teplizumab Is Changing the Conversation
For decades, treatment after a type 1 diabetes diagnosis focused almost entirely on insulin replacement and blood glucose management. While advances in technology have improved care, clinicians have had few ways to address the autoimmune process driving beta-cell loss. That is beginning to change. With the FDA’s expansion of teplizumab-mzwv …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.